Skip to main content
. 2011 Mar 18;1(3):e11. doi: 10.1038/bcj.2011.12

Figure 1.

Figure 1

Influence of the FLT3 kinase on the expression of the LAA PR-3, RHAMM, WT-1, PRAME and Survivin. (a) RS4;11 (FLT3-WT+) cells were treated with FL for a time period of 72 h and the expression of the LAA PR-3, RHAMM, WT-1, PRAME and Survivin was documented via RT–PCR at 8, 12, 24, 48 and 72 h after treatment. (b) RS4;11 (FLT3-WT+) cells were treated with FL, FLT3-siRNA and/or ctrl-siRNA for 72 h, and the expression of the LAA PR-3, RHAMM, WT-1, PRAME and Survivin was analyzed by RT–PCR. (Lanes 1–4 show the expression of the different tumor antigens PR-3, RHAMM, WT-1, PRAME and Survivin in RS4;11 cells treated with FL (lane 1), in RS4;11 cells treated with FLT3-siRNA (lane 2), in RS4;11 cells treated with ctrl-siRNA (lane 3) and in RS4;11 cells without FL (lane 4).) (c) MV4;11 (FLT3-ITD+) cells were treated with the FLT3 kinase inhibitor SU5614 for 72 h, and the expression of the LAA PR-3, RHAMM, WT-1, PRAME and Survivin was documented via RT–PCR at different time points after treatment. The three figures are composed of different gels.